China SXT Pharmaceuticals (SXTC) Other Accumulated Expenses (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Other Accumulated Expenses of $877421.0 for Q1 2026, up 30.11% year-over-year from $674391.0 in Q1 2025, and down 4.72% quarter-over-quarter from $920853.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $877421.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 30.11% year-over-year to $877421.0; the TTM figure through Mar 2026 stood at $877421.0 (up 30.11% YoY), while the FY2026 annual figure was $877421.0, up 30.11% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $877421.0, down from $920853.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $6.2 million in Q3 2024, with the low at $361543.0 in Q1 2024.
- The 5-year median for Other Accumulated Expenses is $920853.0 (2025), against an average of $1.4 million.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses jumped 538.65% in 2024, then slumped 85.18% in 2025.
- China SXT Pharmaceuticals' Other Accumulated Expenses stood at $1.0 million in 2022, then slipped by 5.56% to $972738.0 in 2023, then surged by 538.65% to $6.2 million in 2024, then plunged by 85.18% to $920853.0 in 2025, then fell by 4.72% to $877421.0 in 2026.
- Business Quant data shows SXTC's Other Accumulated Expenses at $877421.0 in Q1 2026, $920853.0 in Q3 2025, and $674391.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | China SXT Pharmaceuticals | 32,029.92 | -28.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 877,421.00 |
| Sep 30, 2025 | 920,853.00 |
| Mar 31, 2025 | 674,391.00 |
| Sep 30, 2024 | 6.21 Mn |
| Mar 31, 2024 | 361,543.00 |
| Sep 30, 2023 | 972,738.00 |
| Mar 31, 2023 | 789,232.00 |
| Sep 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 1.16 Mn |
| Sep 30, 2021 | 906,983.00 |
| Mar 31, 2021 | 819,677.00 |
| Sep 30, 2020 | 734,721.00 |
| Mar 31, 2020 | 287,705.00 |
| Sep 30, 2019 | 172.87 Bn |
| Mar 31, 2019 | 164,676.00 |
| Mar 31, 2018 | 147,119.00 |